Johnson & Johnson Nasal spray

FDA Approves ‘Spravato’ Nasal Spray

FDA approves Johnson & Johnson’s ketamine-derived nasal spray for depression as stand-alone treatment

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

Popular Science · 1d

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

Fox Business · 2d

J&J's ketamine-derived nasal spray approved by FDA to treat depression

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

1don MSN

FDA Approves Nasal Spray for Depression

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

Controlling infections might reduce risk of dementia, study says

Vaccines, antibiotics, antiviral medications and anti-inflammatory drugs are all associated with a reduced risk of dementia, researchers reported in a study published Tuesday in the journal ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

FDA Approves ‘Spravato’ Nasal Spray

Trending now